A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-